PHP
NVAX icon

Parkman Healthcare Partners’s Novavax NVAX Stock Holding History

Parkman Healthcare Partners’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-34,498
Closed -$3.85M – 94
2020
Q4 		$3.85M Buy
34,498
+16,998
+97% +$1.81M 0.99% 42
2020
Q3 		$1.9M Sell
17,500
-22,500
-56% -$2.74M 0.5% 61
2020
Q2 		$3.33M Buy
+40,000
New +$1.53M 0.94% 38

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parkman Healthcare Partners's NVAX Position: Q1 2021 in Review

Parkman Healthcare Partners sold out of Novavax (NVAX) in Q1 2021, closing a stake of 34,498 shares — an estimated $3.85M sold.

Parkman Healthcare Partners first reported a position in NVAX in Q2 2020 and held it in 3 quarters. The position peaked at $3.85M in Q4 2020. 390 funds tracked by Wall St. Rank hold NVAX as of Q1 2021.

  • Parkman Healthcare Partners reported no remaining Novavax position as of Q1 2021 after selling out during the quarter.
  • Parkman Healthcare Partners sold 34,498 Novavax shares in Q1 2021, an estimated $3.85M.
  • Parkman Healthcare Partners first reported a position in Novavax in Q2 2020 and held it in 3 quarters.
  • Parkman Healthcare Partners's Novavax position peaked at $3.85M in Q4 2020.
  • 390 funds tracked by Wall St. Rank held Novavax as of Q1 2021.

Based on Parkman Healthcare Partners's 13F filing for Q1 2021, filed 14 May 2021.